)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
PolyNovo
PolyNovo (PNV) investor relations material
PolyNovo AGM 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.AGM 2026 summary30 Oct, 2026
Opening remarks and agenda
Quorum confirmed; hybrid AGM opened, with shareholders attending in person and online. The meeting began with the FY 2026 annual, directors’ and auditor’s reports.
Two directors retired at the meeting and were thanked for their contributions; a patient story followed Sam Nye’s recovery after a severe shark attack using NovoSorb BTM.
Financial performance review
FY 2026 revenue growth was 21% in constant currency; underlying EBITDA rose 50.4% YoY and free cash flow was AUD 9.4m.
Chair cited no debt, cash generation and only about AUD 1.5m remaining to pay on factory capex; operating and admin costs were stable, while people costs rose about 4%.
Management said profitability is improving but depends on balancing reinvestment with returns; revenue, profitability, cash generation and broader platform use were cited as shareholder value measures.
Board and executive committee updates
Robyn Elliott and Christine Emmanuel-Donnelly retired at the AGM; Charmaine Gittleson joined in April, and Dean Phizacklea and Andrew Price were appointed in September 2026 and stood for election.
CEO Bruce Peatey, Chief Scientific Officer Marthe D’Ombrain, General Counsel and Company Secretary Amy Demediuk, and Chief Manufacturing and Supply Chain Officer Tyson Parker joined the leadership team.
New directors cited experience across clinical and regulatory affairs, international markets, innovation, supply chains, quality and governance.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from PolyNovo
- Sales and EBITDA surged, with robust global growth and a strong innovation pipeline for FY27.PNV
H2 2026 - Revenue and cash flow surged, with new products and expanded capacity driving FY27 growth.PNVTrading update
- Sales up 26% to AUD 68.2M, NovoSorb MTX up 195%, and U.S. PMA submission on track for FY26.PNVH1 2026
- Strong growth and governance reforms mark a year of expansion and leadership transition.PNVAGM 2025
- Record 28.9% sales growth and 149.1% profit increase, fueled by global expansion.PNVH2 2025
- Strong growth, global reach, and governance advances define this year's AGM.PNVAGM 2024
- Record FY24 revenue, first full-year profit, and global expansion drive strong performance.PNVH2 2024
- Record sales, strong cash flow, and global expansion drive continued growth.PNVInvestor Update
- Revenue up 22.8% and net profit up 23.9% in 1H25, with strong global sales and new launches.PNVH1 2025
Next PolyNovo earnings date
H1 202719 Feb, 2027
PolyNovo
Next PolyNovo earnings date
H1 202719 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
PolyNovo Limited is an Australian medical device company specializing in the development and manufacturing of advanced wound care solutions using its proprietary NovoSorb biodegradable polymer technology. The company's flagship product, NovoSorb Biodegradable Temporizing Matrix (BTM), is designed to support dermal regeneration in patients who have suffered tissue loss due to burns, trauma, or surgical procedures. NovoSorb BTM is utilized in various medical applications, including the treatment of complex wounds, chronic ulcers, and surgical wounds. Additionally, PolyNovo is expanding its product portfolio to include applications in hernia repair and other reconstructive surgeries. PolyNovo Limited is headquartered in Port Melbourne, Victoria, Australia, and its shares are listed on the Australian Securities Exchange.